Acute Heart Failure References

Abi Khalil C, Sulaiman K, Singh R, Jayyousi A, Asaad N, AlHabib KF, et al. BMI is inversely correlated to the risk of mortality in patients with type 2 diabetes hospitalized for acute heart failure: Findings from the Gulf aCute heArt failuRE (Gulf-CARE) registry. Int J Cardiol. 2017;241:262–9.

Agostini P, Farmakis DT, García-Pinilla JM, Veli-Pekka Harjola V-P, Karason K, von Lewinski D,,et al. Haemodynamic balance in acute and advanced heart failure: an expert perspective on the role of levosimendan. Card Fail Rev. 2019;5:ePub: 26 August 2019.

Agra Bermejo RM, González Ferreiro R, Varelo Román A, Gómez Otero I, Kreidieh O, Conde Sabarís P, et al. Nutritional status is related to heart failure severity and hospital readmissions in acute heart failure. Int J Cardiol. 2017;230:108–14.

Algarni KD, Elhenawy AM, Magani M, Collins S, Yau TM. Decreasing prevalence but increasing importance of left ventricular dysfunction and reoperative surgery in prediction of mortality in coronary artery bypass surgery: Trends over 18 years. J Thorac Cardiovasc Surg. 2012;144:340–6.

Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2012;17;125:1928–52.

Allen LA, Gheorghiade M, Reid KJ, Dunlay SM, Chan PS, Hauptman PJ, et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes. 2011;4:389–98.

Altenberger J, Gustafsson F, Harjola VP, Karason K, Kindgen-Milles D, Kivikko M et al. Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications. J Cardiovasc Pharmacol. 2018;71:129–36.

Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure. Lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123–33.

Arrigo M, Gayat E, Parenica J, Ishihara S, Zhang J, Choi DJ, et al. Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry. Eur J Heart Fail. 2017;19:201–8.

Avellino A, Collins SP, Fermann GJ. Risk stratification and short term prognosis in acute heart failure syndromes: a review of novel biomarkers. Biomarkers. 2011;16:379–92.

Bart BA, Goldsmith SR, Lee KL, Redfield MM, Felker GM, O'Connor CM, et al. Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. J Card Fail. 2012;18:176–82.

Baysal A, Yanartas M, Dogukan M, Gundogus N, Kocak T, Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. J Cardiothorac Vasc Anesth. 2014;28:586–594.

Biering-Sørensen T, Querejeta Roca G, Hegde SM, Shah AM, Claggett B, Mosley TH Jr, et al. Left ventricular ejection time is an independent predictor of incident heart failure in a community-based cohort. Eur J Heart Fail. 2018;20:1106–14.

Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. Eur Heart J. 2004;25:1614–9.

Bortsova MA, Bautin AE, Yakovlev AS, Fedotov PA, Sazonova YV, Marichev AO, et al. On the possibility to increase sensitivity of diagnostic tests for fixed pulmonary hypertension in heart transplant candidates. Almanac Clin Med. 2019;47:212–20. (In Russian, English summary.)

Brockmeyer M, Lin Y, Karathanos A, Parco C, Krieger T, Heinen Y, et al. Preoperative levosimendan improves survival in patients with low cardiac output syndrome undergoing cardiac surgery: a meta-analysis of randomized controlled trials. ESC Congress, Paris, France, 2019; P272.

Chaudhry SP, Stewart GC. Advanced heart failure: Prevalence, natural history, and prognosis. Heart Fail Clin. 2016;12:323–33.

Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:1242–54.

Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171:369–76.

Constanzo MR. Ultrafiltration in acute heart failure. Card Fail Rev 2019;5:9–18.

Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:1505–35.

De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779–89.

De la Espriella R, Santas E, Miñana G, Bodí V, Valero E, Payá R, et al. Functional mitral regurgitation predicts short-term adverse events in patients with acute heart failure and reduced left ventricular ejection fraction. Am J Cardiol. 2017;120:1344–8.

Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med. 2001;345:574–81.

Ersoy O, Boysan E, Unal EU, Yay K, Yener U, Cicekcioglu F, et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovasc J Afr 2013;24:260–264.

Farmakis D, Alvarez J, Gal TB, Brito D, Fedele F, Fonseca C, et al. Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. Int J Cardiol. 2016;222:303–12.

Farmakis D, Agostoni P, Baholli L, Bautin A, Comin-Colet J, Crespo-Leiro MG, et al. A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: an expert panel consensus. Int J Cardiol. 2019; https://doi.org/ 10.1016/j.ijcard.2019.09.005.

Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805.

Grodin JL, Carter S, Bart BA, Goldsmith SR, Drazner MH, Tang WHW. Direct comparison of ultrafiltration to pharmacological decongestion in heart failure: a per-protocol analysis of CARRESS-HF. Eur J Heart Fail. 2018;20:1148–56.

Harjola VP, Giannakoulas G, von Lewinski D, Matskeplishvili S, Mebazaa A, Papp Z, et al. Use of levosimendan in acute heart failure. Eur Heart J Suppl. 2018;20:I2–I10.

Harjola VP, Parissis J, Brunner-La Rocca HP, Čelutkienė J, Chioncel O, Collins SP, et al. Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2018;20:1081–99.

Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, Chioncel O, et al. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017;19:821–36.

Harrison RW, Hasselblad V, Mehta RH, Levin R, Harrington RA, Alexander JH. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2013;27:1224–1232.

Honda S, Nagai T, Nishimura K, Nakai M, Honda Y, Nakano H, et al. Long-term prognostic significance of urinary sodium concentration in patients with acute heart failure. Int J Cardiol. 2018;254:189–94.

Horiuchi Y, Tanimoto S, Latif AHMM, Urayama KY, Aoki J, Yahagi K, et al. Identifying novel phenotypes of acute heart failure using cluster analysis of clinical variables. Int J Cardiol. 2018;262:57–63.

Ivanova-Razumova T, Baigalkanova AI, Ahash U, Janatkyzy A, Kalieve R, Alpysbaeva TM, et al. Levosimendan use in pediatric patients with end-stage heart failure: single center experience. Sixth World Congress on Heart Failure, 25-–28 May 2019, Greece:P1035.

Jin M, Wei S, Wang K, Xu X, Yao W, Zhang H, et al. Predictors of long-term mortality in patients with acute heart failure. Int Heart J. 2017;58:409–15.

Johnson FL. Pathophysiology and Etiology of Heart Failure. Cardiol Clin. 2014;32:9–19.

Kagiyama N, Matsue Y. The time-to-treatment concept in acute heart failure: Lessons and implications from REALITY-AHF. Anatol J Cardiol. 2018;20:125–9.

Kaltsi I, Angelopoulous E, Tzanis G, Sideris A, Tyrovolas, Kokkoris S. Contribution of levosimendan in weaning from mechanical ventilation in patients with left ventricular dysfunction: a pilot study. Crit Care Res Pract. 2019 Jul 24;2019:7169492. 

Kazory A, Costanzo MR. Extracorporeal isolated ultrafiltration for management of congestion in heart failure and cardiorenal syndrome. Adv Chronic Kidney Dis. 2018;25:434–42.

Kiernan MS, Stevens SR, Tang WHW, Butler J, Anstrom KJ, Birati EY, et al. Determinants of diuretic responsiveness and associated outcomes during acute heart failure hospitalization: an analysis from the NHLBI heart failure network clinical trials. J Card Fail. 2018. [Epub ahead of print].

Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O'Connor CM, Felker GM. Troponin elevation in heart failure: prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010;56:1071–8.

Komamura K. Similarities and differences between the pathogenesis and pathophysiology of diastolic and systolic heart failure. Cardiol Res Pract. 2013;2013:824135.

Kurmani S, Squire I. Acute heart failure: Definition, classification and epidemiology. Curr Heart Fail Rep. 2017;14:385–92.

Landoni G, Lomivorotov VV, Alvaro G, Lobreglio R, Pisano A, Guarracino F, et al. Levosimendan for hemodynamic support after cardiac surgery. N Engl J Med. 2017;376:2021–31.

Lee DS, Lee JS, Schull MJ, Borgundavaag B, Edmonds ML, Ivankovic M, et al. Prospective validation of the emergency heart failure mortality risk grad for acute heart failure: The Acute Congestive heart failure Urgent care Evaluation (ACUTE) Study. Circulation. 2018. [Epub ahead of print].

Lee DS, Schull MJ, Alter DA, Austin PC, Laupacis A, Chong A, et al. Early deaths in patients with heart failure discharged from the emergency department: a population-based analysis. Circ Heart Fail. 2010;3:228–35.

Legrand M, Ludes PO, Massy Z, Rossignol P, Parenica J, Park JJ, et al. Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications. Clin Res Cardiol. 2018;107:214–21.

Leppikangas H, Järvelä K, Sisto T, Maaranen P, Virtanen M, Lehto P et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. Br J Anaesth 2011;106:298–304.

Levin R, Degrange M, Del Mazo C, Tanus E, Porcile R. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol. 2012;17:125–130.

Levy B, Buzon J, Kimmoun A. Inotropes and vasopressors use in cardiogenic shock: when, which and how much? Curr Opin Crit Care. 2019;25:384–90.

Llorens P, Javaloyes P, Martín-Sánchez FJ, Jacob J, Herrero-Puente P, Gil V, et al. Time trends in characteristics, clinical course, and outcomes of 13,791 patients with acute heart failure. Clin Res Cardiol. 2018;107:897–913.

Luk A, Groarke JD, Desai AS, Mahmood SS, Gopal DM, Joyce E, et al. First spot urine sodium after initial diuretic identifies patients at high risk for adverse outcome after heart failure hospitalization. Am Heart J. 2018;203:95–100.

Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, et al. EURObservational Research Programme:regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15:808–17.

Marchetti M, Benedetti A, Mimoz O, Lardeur JY, Guenezan J, Marjanovic N. Predictors of 30-day mortality in patients admitted to ED for acute heart failure. Am J Emerg Med. 2017;35:444–7.

Marti CN, Georgiopoulou VV, Kalogeropoulos AD. Acute heart failure: Patient characteristics and pathophysiology. Curr Heart Fail Rep. 2013;10:427–33.

Matsue Y, Damman K, Voors AA, Kagiyama N, Yamaguchi T, Kuroda S, et al. Time-to-flurosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69:3042–51.

Matsushita M, Shirakabe A, Hata N, Shinada T, Kobayashi N, Tomita K, et al. Associated between the body mass index and the clinical findings in patients with acute heart failure: evaluation of the obesity paradox in patients with severely decompressed acute heart failure. Heart Vessels. 2017;32:600–8.

McCabe N, Butler J, Dunbar SB, Higgins M, Reilly C. Six-minute walk distance predicts 30-day readmission after acute heart failure hospitalization. Heart Lung. 2017;46:287–92.

McMurray J, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart. 2000;83:596–602.

Mebazaa A, Pitsis AA, Rudiger A, Toller W, Longrois D, Ricksten S-E, et al. Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery. Critical Care. 2010;14:201–14.

Mebazaa A, Combes A, van Diepen S, Hollinger A, Katz JN, Landoni G, et al. Management of cardiogenic shock complicating myocardial infarction. Intensive Care Med. 2018;44:760–73. 

Mehta RH, Leimberger JD, van Diepen S, Meza J, Wang A, Jankowich R, et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med. 2017;376:2032–42.

Mentz RJ & O'Connor CM. Pathophysiology and clinical evaluation of acute heart failure. Nat Rev Cardiol. 2016;13:28–35.

Metra M, E, Nicolò Dasseni N. The New Heart Failure Association Ddefinition of Aadvanced Hheart Ffailure. Card Fail Rev. 2019; 5:5–8.

Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93:1137–46.

Miró Ò, Martínez G, Masip J, Gil V, Martín-Sánchez FJ, Llorens P, et al. Effects on short term outcome of non-invasive ventilation use in the emergency department to treat patients with acute heart failure: A propensity score-based analysis of the EAHFE Registry. Eur J Intern Med. 2018;53:45–51.

Mueller C, Christ M, Cowie M, Cullen L, Maisel AS, Masip J, et al. European Society of Cardiology – Acute Cardiovascular Care Association position paper on acute heart failure: a call for interdisciplinary care. Eur Heart J. 2017;6:81–6.

Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–96.

National Institute for Health and Care Excellence (NICE). Chronic heart failure in adults: management. 2010. Available from https://www.nice.org.uk/guidance/Cg108 (accessed August 2018).

Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola V-P, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006;27: 2725–36.

Nieminen MS, Buerke M, Cohen-Solál A, Costa S, Édes I, Erlikh A, et al. The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion. Int J Cardiol. 2016;218:150–7.

Normand C, Kaye DM, Povsic TJ, Dickstein K. Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. Lancet 2019;393:1045–55.

Packer M, O'Connor C, McMurray JJV, Wittes J, Abraham WT, Anker SD, et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017;376:1956–64.

Pang PS, Schuur JD. Emergency departments, acute heart failure, and admissions: one size does not fit all. JACC Heart Fail. 2014;2:278–80.

Papp Z, Édes I, Fruhwald S, De Hert SG, Salmenperä M, Leppikangas H, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012;159:82–7.

Park D, McManus D, Darling C, Goldberg JH, Gore JM, Lessard D, et al. Recent trends in the characteristics and prognosis of patients hospitalized with acute heart failure. Clin Epidemiol. 2011;3:295–303.

Platz E, Jhund PS, Campbell RT, McMurray JJ. Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review. Eur J Heart Fail. 2015;17:906–16.

Polsinelli VB, Marteau L, Shah SJ. The role of splanchnic congestion and the intestinal microenvironment in the pathogenesis of advanced heart failure. Curr Opin Support Palliat Care. 2019;13:24-–30.

Pölzl G. Levosimendan in acute and advanced heart failure: still some chapters to be written. Eur Heart J Suppl. 2018;20:l1.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;18:891–975.

Prior DL, Flaim BD, MacIsaac AI, Yii MY. Pre-operative use of levosimendan in two patients with severe aortic stenosis and left ventricular dysfunction. Heart Lung Circ 2006;15:56–58.

Qiu J, Jia L, Hao Y, Huang S, Ma Y, Li X, et al. Efficacy and safety of levosimendan in patients with acute right heart failure: A meta-analysis. Life Sci. 2017;184:30–6.

Russell FM, Ehrman RR. A modified lung and cardiac ultrasound protocol saves time and rules in the diagnosis of acute heart failure. J Emerg Med. 2017;52:839–45.

Santillo E, Migale M, Massini C, Incalzi RA. Levosimendan for perioperative cardioprotection: myth or reality? Curr Cardiol Rev. 2018;14:142–52.

Schiff GD, Fung S, Speroff T, McNutt RA. Decompensated heart failure: symptoms, patterns of onset, and contributing factors. Am J Med. 2003;114:625–30.

Shah P, Pellicori P, Cuthbert J, Clark AL. Pharmacological and non-pharmacological treatment for decompensated heart failure: what is new? Curr Heart Fail Resp. 2017;14:147–57.

Shang G, Yang X, Song D, Ti Y, Shang Y, Wang Z, et al. Effects of levosimendan on patients with heart failure complicating acute coronary syndrome: a meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs. 2017;17:453–63.

Shibata N, Sumi T, Umemoto N, Kajiura H, Inoue S, Lio Y, et al. Combination assessment of renal and hepatic dysfunction improves the predictability of prognosis in patients with acute decompensated failure. ESC Congress 2019; P5410.

Skaluba SJ, Litwin SE. Mechanisms of exercise intolerance: insights from tissue Doppler imaging. Circulation. 2004;109:972–7.

Takabayashi K, Kitaguchi S, Iwatsu K, Morikami Y, Ichinohe T, Yamamoto T, et al. A decline in activities of daily living due to acute heart failure is an independent risk factor of hospitalization for heart failure and mortality. J Cardiol. 2018. [Epub ahead of print].

Tanai E & Frantz S. Pathophysiology of heart failure. Compr Physiol. 2015;6:187–214.

Tena MÁ, Urso S, González JM, Santana L, Sadaba R, Juarez P, et al. Levosimendan versus placebo in cardiac surgery: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2018;27:677–85.

Thorlacius EM, Suominen PK, Wåhlander H, Keski-Nisula J, Vistnes M, Ricksten SE. The effect of levosimendan versus milrinone on the occurrence rate of acute kidney injury following congenital heart surgery in infants: a randomized clinical trial. Pediatr Crit Care Med. 2019 Jul 3; doi: 10.1097/PCC.0000000000002017.

Thorvaldsen T, Claggett BL, Shah A, Cheng S, Agarwal SK, Wruck LM, et al. Predicting risk in patients hospitalized for acute decompensated heart failure and preserved ejection fraction: The Atherosclerosis Risk in Communities Study Heart Failure Community Surveillance. Circ Heart Fail. 2017;10. pii: e003992.

Toller W, Heringlake M, Guarracino F, Algotsson L, Alvarez J, Argyriadou H, et al. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. Int J Cardiol 2015;184:323–336.

Valbusa F, Agnoletti D, Scala L, Grillo C, Arduini P, Bonapace S, et al. Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure. Int J Cardiol. 2018;265:162–8.

Valbusa F, Bonapace S, Agnoletti D, Scala L, Grillo C, Arduini P, et al. Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. PLoS One. 2017;12:e0173398.

van Diepen S, Mehta RH, Leimberger JD, Goodman SG, Fremes S, Jankowich R, Heringlake M, et al. Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. J Thorac Cardiovasc Surg. 2019 Jun 21. pii: S0022-5223(19)31278-4. 

Wakai A, McCabe A, Kidney R, Brooks SC, Seupaul RA, Diercks DB, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev. 2013;8:CD005151.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–327.

Yip G, Wang M, Zhang Y, Fung JW, Ho PY, Sanderson JE. Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: time for a redefinition? Heart. 2002;87:121–5.

Zhou S, Zhang L, Li J. Effect of levosimendan in patients with acute decompensated heart failure: A meta-analysis. Herz. 2018. [Epub ahead of print].

Homepage

Homepage

Medical information for healthcare professionals about acute and advanced heart failure. Find relevant resources, links, publications, videos and events.

Advanced Heart Failure

Advanced Heart Failure

Explore the epidemiology, pathophysiology, diagnosis, prognosis and more of advanced heart failure.


 

Login/ Register Maximise Minimise